BC Innovations | Apr 25, 2019
Emerging Company Profile

miR Scientific: spotting aggression with RNA in urine

miR has paired its panel of urine-based RNAs with a statistical algorithm for accurate diagnosis of aggressive bladder and prostate cancers, sparing patients with lower-grade tumors from invasive biopsies and unnecessary drug treatments. The company's...
BC Week In Review | Sep 7, 2018
Financial News

Exosome play Evox aims for clinic with £35.5M series B

Evox Therapeutics Ltd. (Oxford, U.K.) raised on Sept. 3 £35.5 million ($45.9 million) in a series B round led by Redmile Group. Also participating were GV, Cowen Healthcare Investments, Panacea Healthcare Venture, Borealis Ventures, Oxford...
BC Extra | Sep 4, 2018
Financial News

Exosome play Evox aims for clinic with £35.5M series B

Evox Therapeutics Ltd. (Oxford, U.K.) raised £35.5 million ($45.9 million) in a series B round led by Redmile Group. Also participating were GV, Cowen Healthcare Investments, Panacea Healthcare Venture, Borealis Ventures, Oxford Sciences Innovation (OSI),...
BC Week In Review | Jun 29, 2018
Company News

Bio-Techne acquiring Exosome Diagnostics for $250M

Research supplier Bio-Techne Corp. (NASDAQ:TECH) will acquire cancer diagnostic company Exosome Diagnostics Inc. (Waltham, Mass.) for $250 million in cash. Exosome shareholders will also be eligible for $325 million in milestones based on future earnings...
BC Extra | Jun 26, 2018
Company News

Bio-Techne acquiring Exosome Diagnostics for $250M

Research supplier Bio-Techne Corp. (NASDAQ:TECH) will acquire cancer diagnostic company Exosome Diagnostics Inc. (Waltham, Mass.) for $250 million in cash. Exosome shareholders will also be eligible for $325 million in milestones based on future earnings...
BC Innovations | Aug 31, 2017
Translation in Brief

Bringing home exosomes

Researchers at the University of California San Diego published the first proof-of-concept data showing Biological Dynamics Inc. 's exosome-on-a-chip platform can isolate the extracellular vesicles and their proteins in under 30 minutes, without damaging them....
BC Innovations | Jun 22, 2017
Targets & Mechanisms

Exosomes deliver

Codiak BioSciences Inc. founder Raghu Kalluri has published the first animal data demonstrating exosomes can be used as drug delivery vehicles to treat cancer -- not just diagnose it. The findings also mark the unveiling...
BC Innovations | Jun 22, 2017
Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Diagnostic assays; cell-free assays; plasma markers A five-protein signature in extracellular vesicles isolated from plasma could help diagnose PDAC. The assay involves two steps: addition of patient plasma samples to a gold plasmonic chip-based...
BioCentury | May 26, 2017
Emerging Company Profile

Bypassing biopsies

Nanostics Inc. is analyzing biomarkers on tumor-derived vesicles in blood to increase the accuracy of routine prostate cancer screening, and provide a readout of a tumor's aggressiveness. When used with routine PSA screening, the company’s...
BC Extra | Mar 24, 2017
Clinical News

Donor exosomes could provide an early warning of transplant failure

Exosomes from donor tissue may provide an early warning of transplant failure that could aid patient treatment. A group from the University of Pennsylvania showed that donor exosome profiles could be measured in transplant patients...
Items per page:
1 - 10 of 54
BC Innovations | Apr 25, 2019
Emerging Company Profile

miR Scientific: spotting aggression with RNA in urine

miR has paired its panel of urine-based RNAs with a statistical algorithm for accurate diagnosis of aggressive bladder and prostate cancers, sparing patients with lower-grade tumors from invasive biopsies and unnecessary drug treatments. The company's...
BC Week In Review | Sep 7, 2018
Financial News

Exosome play Evox aims for clinic with £35.5M series B

Evox Therapeutics Ltd. (Oxford, U.K.) raised on Sept. 3 £35.5 million ($45.9 million) in a series B round led by Redmile Group. Also participating were GV, Cowen Healthcare Investments, Panacea Healthcare Venture, Borealis Ventures, Oxford...
BC Extra | Sep 4, 2018
Financial News

Exosome play Evox aims for clinic with £35.5M series B

Evox Therapeutics Ltd. (Oxford, U.K.) raised £35.5 million ($45.9 million) in a series B round led by Redmile Group. Also participating were GV, Cowen Healthcare Investments, Panacea Healthcare Venture, Borealis Ventures, Oxford Sciences Innovation (OSI),...
BC Week In Review | Jun 29, 2018
Company News

Bio-Techne acquiring Exosome Diagnostics for $250M

Research supplier Bio-Techne Corp. (NASDAQ:TECH) will acquire cancer diagnostic company Exosome Diagnostics Inc. (Waltham, Mass.) for $250 million in cash. Exosome shareholders will also be eligible for $325 million in milestones based on future earnings...
BC Extra | Jun 26, 2018
Company News

Bio-Techne acquiring Exosome Diagnostics for $250M

Research supplier Bio-Techne Corp. (NASDAQ:TECH) will acquire cancer diagnostic company Exosome Diagnostics Inc. (Waltham, Mass.) for $250 million in cash. Exosome shareholders will also be eligible for $325 million in milestones based on future earnings...
BC Innovations | Aug 31, 2017
Translation in Brief

Bringing home exosomes

Researchers at the University of California San Diego published the first proof-of-concept data showing Biological Dynamics Inc. 's exosome-on-a-chip platform can isolate the extracellular vesicles and their proteins in under 30 minutes, without damaging them....
BC Innovations | Jun 22, 2017
Targets & Mechanisms

Exosomes deliver

Codiak BioSciences Inc. founder Raghu Kalluri has published the first animal data demonstrating exosomes can be used as drug delivery vehicles to treat cancer -- not just diagnose it. The findings also mark the unveiling...
BC Innovations | Jun 22, 2017
Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Diagnostic assays; cell-free assays; plasma markers A five-protein signature in extracellular vesicles isolated from plasma could help diagnose PDAC. The assay involves two steps: addition of patient plasma samples to a gold plasmonic chip-based...
BioCentury | May 26, 2017
Emerging Company Profile

Bypassing biopsies

Nanostics Inc. is analyzing biomarkers on tumor-derived vesicles in blood to increase the accuracy of routine prostate cancer screening, and provide a readout of a tumor's aggressiveness. When used with routine PSA screening, the company’s...
BC Extra | Mar 24, 2017
Clinical News

Donor exosomes could provide an early warning of transplant failure

Exosomes from donor tissue may provide an early warning of transplant failure that could aid patient treatment. A group from the University of Pennsylvania showed that donor exosome profiles could be measured in transplant patients...
Items per page:
1 - 10 of 54